Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Nov;5(11):845-847.
doi: 10.1016/S2213-8587(17)30320-0. Epub 2017 Sep 13.

Pioglitazone versus sulfonylureas: cardiovascular outcomes with older diabetes drugs

Vivian A Fonseca  1 , Dragana Lovre  2
Affiliations
Comment

Pioglitazone versus sulfonylureas: cardiovascular outcomes with older diabetes drugs

Vivian A Fonseca et al. Lancet Diabetes Endocrinol. 2017 Nov.
No abstract available

PubMed Disclaimer

Comment on

  • Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.
    Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, Rivellese AA, Squatrito S, Giorda CB, Sesti G, Mocarelli P, Lucisano G, Sacco M, Signorini S, Cappellini F, Perriello G, Babini AC, Lapolla A, Gregori G, Giordano C, Corsi L, Buzzetti R, Clemente G, Di Cianni G, Iannarelli R, Cordera R, La Macchia O, Zamboni C, Scaranna C, Boemi M, Iovine C, Lauro D, Leotta S, Dall'Aglio E, Cannarsa E, Tonutti L, Pugliese G, Bossi AC, Anichini R, Dotta F, Di Benedetto A, Citro G, Antenucci D, Ricci L, Giorgino F, Santini C, Gnasso A, De Cosmo S, Zavaroni D, Vedovato M, Consoli A, Calabrese M, di Bartolo P, Fornengo P, Riccardi G; Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group; Italian Diabetes Society. Vaccaro O, et al. Lancet Diabetes Endocrinol. 2017 Nov;5(11):887-897. doi: 10.1016/S2213-8587(17)30317-0. Epub 2017 Sep 13. Lancet Diabetes Endocrinol. 2017. PMID: 28917544 Clinical Trial.

Similar articles

See all similar articles

References

    1. Standards of Medical Care in Diabetes 2017: summary of revisions. Diabetes Care. 2017;40(suppl 1):S4–5. No authors listed. - PubMed
    1. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2017 executive summary. Endocr Pract. 2017;23:207–38. - PubMed
    1. Marx N, Rosenstock J, Kahn SE, et al. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA) Diab Vasc Dis Res. 2015;12:164–74. - PMC - PubMed
    1. Nathan DM, Buse JB, Kahn SE, et al. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE) Diabetes Care. 2013;36:2254–61. - PMC - PubMed
    1. Vaccaro O, Masulli M, Nicolucci A, et al. for the Thiazolidinediones Or Sulphonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017 published online Sept 13. http://dx.doi.org/10.1016/S2213-8587(17)30317-0. - DOI - PubMed

LinkOut - more resources